This article has been updated to include comments from a conference call and a stock quote.
 
NEW YORK (GenomeWeb News) – Genomic Health said today that sales for its Oncotype Dx breast cancer assay rose 78 percent for the first quarter ended March 31, and the firm shaved 4.3 percent off of its net loss year over year.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.